Drug Profile
Cedefingol
Alternative Names: SPC 101210Latest Information Update: 30 Jun 1998
Price :
$50
*
At a glance
- Originator Research Triangle Park Laboratories
- Class Acetamides; Antineoplastics; Antipsoriatics; Small molecules
- Mechanism of Action Protein kinase C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Psoriasis
Most Recent Events
- 30 Jun 1998 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 30 Jun 1998 Discontinued - Preclinical for Psoriasis in USA (unspecified route)
- 28 Feb 1995 Preclinical development for Cancer in USA (unspecified route)